A number of countries in Central and Eastern Europe and the former Soviet Union are implementing drug substitution treatment for opioid dependent people. The most common opioid agonist treatment drugs—methadone and buprenorphine—have been synthesized and marketed for many years by a number of pharmaceutical companies, and are offered at varying market prices.
Scientific evidence suggests that substitution treatment can help reduce criminality, infectious diseases and drug-related deaths as well as improve the physical, social and psychological well-being of patients. From the perspective of HIV prevention, it is vital to bring as many (injecting) opioid users into treatment and health maintenance services. In many countries substitution treatment is already making a significant contribution towards reaching this goal. It is, therefore, important to further promote substitution treatment and make this type of treatment as affordable as possible.
For this reason, Central and Eastern European Harm Reduction Network (CEEHRN), in cooperation with UNAIDS, has compiled this overview of market prices of methadone and buprenorphine produced by various producers and vendors. The overview, which is periodically updated, is intended to become a useful tool for both specialists in substitution treatment and those starting to implement this type of treatment in their countries.